Aprogen pharmaceuticals,Inc.

KSE 003060.KS

Aprogen pharmaceuticals,Inc. Cash and Short-Term Investments for the year ending December 31, 2023: USD 7.72 M

Aprogen pharmaceuticals,Inc. Cash and Short-Term Investments is USD 7.72 M for the year ending December 31, 2023, a -90.14% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Aprogen pharmaceuticals,Inc. Cash and Short-Term Investments for the year ending December 31, 2022 was USD 78.27 M, a -25.15% change year over year.
Aprogen pharmaceuticals,Inc. Cash and Short-Term Investments for the year ending December 31, 2021 was USD 104.57 M, a -44.45% change year over year.
Aprogen pharmaceuticals,Inc. Cash and Short-Term Investments for the year ending December 31, 2020 was USD 188.26 M, a 136.08% change year over year.
Aprogen pharmaceuticals,Inc. Cash and Short-Term Investments for the year ending December 31, 2019 was USD 79.74 M, a 42.80% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

KSE: 003060.KS

Aprogen pharmaceuticals,Inc.

CEO	Mr. Jeong-Chool Kim
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	Halla Sigma Valley 442-2
Employees	377
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Dental Care Drugstores & Retail Pharmacies Eyewear Personal Care Pet Food

Description

Aprogen pharmaceuticals,Inc. manufactures and sells pharmaceutical products primarily in South Korea. It offers approximately 200 types of medicines, including ethical and over the counter drugs. The company offers its drugs for transfusion, digestive system, osteoarthritis, skeletal muscle relaxants, NSAIDs, osteoporosis, circulatory system, endocrine, respiratory system, urinary system, depilatory, antihistamines and antiallergics, obesity, brain function, neurologics, and male pattern hair loss. It also provides anti-biotic, anti-fungal, anti-viral, anti-ulcerant, anti-epliepsy products; external agents; anti-cancer drugs; amino-acid nutrient transfusion agents; and cosmetics. The company was formerly known as Schnell Biopharmaceuticals, Inc. and changed its name to Aprogen pharmaceuticals,Inc. in April 2017. Aprogen pharmaceuticals,Inc. was founded in 1960 and is headquartered in Seongnam, South Korea.

Key trends

Past 5 years